Zubin Master, PhD

Associate Professor of Biomedical Ethics Biomedical Ethics Research Program and Center for Regenerative Medicine Mayo Clinic

Dr. Zubin Master is an Associate Professor at Mayo Clinic’s Biomedical Ethics Research Program and the Center for Regenerative Medicine. Previously, he was an Associate Professor at the Alden March Bioethics Institute of Albany Medical College, Research Associate for University of Alberta’s Health Law Institute, and has held several adjunct or visiting professor appointments at the University of Montreal, the National Institute of Environmental Health Sciences (NIH), and the Ottawa Hospital Research Institute. Dr. Master also worked in public service as a Senior Policy Advisor at Health Canada where he led the development of Health Canada’s Scientific Integrity Framework and developed regulations under Canada’s Assisted Human Reproduction Act. He holds an undergraduate degree in genetics from York University, a PhD in cellular and molecular biology from the University of Toronto, and a certificate in clinical ethics consultation from Albany Medical College. He completed post-doctoral fellowships in bioethics and health policy at Dalhousie University and the University of British Columbia. Dr. Master serves on several scientific committees, including the International Society for Stem Cell Research’s Education Committee and is an ex-officio for the Public Policy Committee. He is also an Associate Editor for the journal Accountability in Research and has held various other editorial positions.

Dr. Master’s research interests broadly cover the ethical and policy issues related to stem cells and regenerative medicine, genetics, research ethics, and the responsible conduct of research. Dr. Master is interested in understanding how the beliefs and perceptions of patients and physicians surrounding scientific evidence impact how health care decisions are made, especially as they relate to experimental medicine. Much of his work centers on analyzing the direct-to-consumer market of stem cell treatments. He is also interested in ethical and policy issues related to Right to Try and the FDA’s Expanded Access Program.